Oncology Institute (TOI) grants 70,270 RSUs to Chief Clinical Officer Langsam

Rhea-AI Filing Summary

Langsam Jeffrey reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. reported that its Chief Clinical Officer, Jeffrey Langsam, received a grant of 70,270 shares of common stock in the form of restricted stock units. These RSUs were granted at no cash cost per share and increase his direct holdings to 127,650 shares after the award.

The footnote explains that one quarter of the RSUs will vest on the first anniversary of the Vesting Commencement Date, with the remaining units vesting in three equal annual installments on each of the next three anniversaries. All RSUs are subject to continued service with the company through the respective vesting dates.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Langsam Jeffrey

Role Chief Clinical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	70,270	$0.00	--

Holdings After Transaction: Common Stock — 127,650 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 70,270 shares Post-transaction holdings: 127,650 shares Grant price per share: $0.0000 per share +2 more

5 metrics

RSU grant size 70,270 shares Restricted stock unit award to Chief Clinical Officer

Post-transaction holdings 127,650 shares Total common stock held directly after RSU grant

Grant price per share $0.0000 per share Reported transaction price for RSU award

Initial vesting 1/4 of RSUs Vests on first anniversary of Vesting Commencement Date

Remaining vesting schedule 3 equal annual installments After first anniversary, over next three anniversaries

Key Terms

Restricted Stock Units (RSUs), Vesting Commencement Date, continued service, Common Stock

4 terms

Restricted Stock Units (RSUs) financial

"Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Vesting Commencement Date financial

"on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

continued service financial

"subject to continued service with the Company through such vesting dates"

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Langsam Jeffrey

(Last) (First) (Middle)

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Clinical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		A		70,270(1)	A	$0	127,650	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Jeffrey Langsam	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TOI disclose for Jeffrey Langsam on this Form 4?

TOI disclosed that Chief Clinical Officer Jeffrey Langsam received a grant of 70,270 restricted stock units of common stock. The award was reported as an acquisition at no cash cost per share and increased his directly held position to 127,650 shares after the transaction.

How many TOI shares does Jeffrey Langsam hold after this RSU grant?

After the RSU grant, Jeffrey Langsam is reported as directly holding 127,650 shares of TOI common stock. This figure includes the 70,270 restricted stock units awarded in the reported transaction, reflecting his updated ownership position following the grant acquisition disclosed on the Form 4.

How do the TOI restricted stock units granted to Jeffrey Langsam vest over time?

The RSUs vest over four years. One quarter of the units vests on the first anniversary of the Vesting Commencement Date, and the remaining RSUs vest in three equal annual installments on each of the next three anniversaries, subject to his continued service with the company.

Did Jeffrey Langsam pay any purchase price for the TOI RSU award?

No cash purchase price is associated with this RSU award, as the transaction price per share is reported as 0.0000. Restricted stock units are typically granted as part of equity compensation and convert into shares upon vesting if the service conditions are satisfied.

What role does Jeffrey Langsam hold at Oncology Institute, Inc. in this filing?

In this filing, Jeffrey Langsam is identified as an officer of Oncology Institute, Inc., serving as Chief Clinical Officer. The reported RSU award reflects part of his equity-based compensation and is subject to multi-year vesting tied to continued service with the company.